Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation
Clinical trial NCT06360250 · UNKNOWN
Trial details
- NCT number
- NCT06360250
- Sponsor
- Changchun BCHT Biotechnology Co.
- Status
- UNKNOWN
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-10
- Primary completion
- 2024-10-30
- Enrollment
- 190
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.